ArticleTherapeutic advances in medical oncology2026
HAIC combined with lenvatinib and tislelizumab for HCC with concurrent PVTT and pulmonary metastasis: a multicenter propensity score matching analysis.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with hepatocellular carcinoma (HCC) presenting with both portal vein tumor thrombus (PVTT) and pulmonary metastasis (PM) have a particularly poor prognosis and limited treatment options. Hepatic arterial infusion chemotherapy (HAIC)-based combination therapy has shown promising activity in advanced HCC, but evidence in this high-risk population remains limited. Objectives: To evaluate the efficacy and safety of HAIC combined with lenvatinib and tislelizumab (HLP) in patients with HCC with concurrent PVTT and PM. Design: Multicenter retrospective cohort study with propensity score matching (PSM). Methods: Treatment-naïve patients with HCC with concurrent PVTT and PM who received lenvatinib plus tislelizumab (LP), with or without HAIC, between June 2018 and June 2024 were included. PSM was performed to balance baseline characteristics between treatment groups. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). Results: A total of 262 patients were enrolled, including 114 patients in the HLP group and 148 patients in the LP group. After 1:1 PSM, 96 matched pairs were analyzed. The HLP group achieved significantly longer median OS than the LP group (15.1 vs 7.0 months; hazard ratio (HR), 0.55; 95% confidence interval (CI), 0.40-0.76; Conclusion: In patients with HCC with concurrent PVTT and PM, HLP was associated with improved survival outcomes and tumor response compared with lenvatinib plus tislelizumab alone, with a manageable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.